Johnson & Johnson stock holds steady as MedTech growth and Kenvue spin-off reshape earnings profile
Published on 07/19/2026 at 20:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock reflects a transformed earnings profile after the separation of its consumer health business and continues to be driven primarily by its Innovative Medicine and MedTech segments, with 2024 guidance calling for mid-single-digit operational sales growth according to recent investor materials from Johnson & Johnson.
Innovative Medicine and MedTech drive post-spin revenue mix
Johnson & Johnson (ISIN US4781601046) completed the separation of its consumer health business through the Kenvue spin-off in 2023, leaving the company focused on two core segments: Innovative Medicine and MedTech, as described in company filings and presentations on its investor relations site Johnson & Johnson Investor Relations.
For the full year 2023, Johnson & Johnson reported total sales of approximately $85 billion on a continuing-operations basis, with Innovative Medicine generating the majority of revenue and MedTech contributing a significant and growing share, according to data summarized in its 2023 annual report and financial highlights on the same investor relations platform Johnson & Johnson 2023 results.
Within this mix, the Innovative Medicine segment includes key therapeutic areas such as oncology, immunology, neuroscience, and cardiovascular, while the MedTech segment spans surgery, orthopaedics, interventional solutions, and vision, all of which are detailed in segment breakdowns available in Johnson & Johnson corporate materials on its investor relations site Johnson & Johnson business overview.
2023 sales near $85 billion and guidance for continued growth
According to the 2023 annual report and associated earnings commentary, Johnson & Johnson recorded around $85 billion in sales for 2023, with the continuing operations figure reflecting the removal of the consumer health activities that now form Kenvue; this followed 2022 sales in a similar range, resulting in relatively stable year-on-year reported revenue while the underlying mix shifted toward pharmaceuticals and MedTech Johnson & Johnson 2023 Form 10-K.
Management guidance for 2024, as outlined in recent investor presentations and transcripts, points to operational sales growth in the mid-single-digit percentage range, reflecting expectations for continued demand in key Innovative Medicine franchises and ongoing recovery and innovation-driven expansion in MedTech, including procedure volume normalization in several categories Johnson & Johnson 2024 outlook.
Within Innovative Medicine, company commentary highlights contributions from oncology and immunology therapies as important drivers of the projected growth, while in MedTech the company points to areas such as electrophysiology, contact lenses and surgical technologies as underpinning its medium-term expectations, based on product and pipeline summaries in its investor materials Johnson & Johnson portfolio.
More on Johnson & Johnson fundamentals
Investors can explore detailed segment data, pipeline information and historical financials for Johnson & Johnson, including its Innovative Medicine and MedTech businesses, through the dedicated ISIN hub and the companys investor relations site.
Key products support MedTech expansion
Johnson & Johnsons MedTech business includes a range of devices and solutions that support surgical, orthopaedic, cardiovascular and eye-care procedures, and the company has highlighted this segment as a growth pillar in its post-Kenvue structure, according to its MedTech strategy materials on the investor relations site Johnson & Johnson MedTech overview.
Recent product introductions and technology enhancements in areas such as minimally invasive surgery and interventional cardiology are described by the company as important for capturing procedure growth and improving outcomes, which in turn can support both revenue growth and margin performance over time, based on the qualitative commentary in these strategy documents MedTech innovation at Johnson & Johnson.
Johnson & Johnson stock in the market context
Johnson & Johnson stock is listed on the New York Stock Exchange and is a component of major U.S. equity indices, including the Dow Jones Industrial Average and the S&P 500, according to exchange and index provider information summarized on financial data portals that track large-cap U.S. healthcare names Johnson & Johnson stock profile.
Market data providers present Johnson & Johnson as one of the largest healthcare companies globally by market capitalization, with a valuation typically measured in the hundreds of billions of U.S. dollars, reflecting both the scale of its pharmaceutical portfolio and the breadth of its MedTech presence across multiple therapeutic and procedural areas, based on aggregated market-capitalization rankings referenced in recent company and industry materials Johnson & Johnson market data.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: NYSE: JNJ
- Trading venue: NYSE
- Sector / Industry: Health Care / Pharmaceuticals and MedTech
- Index membership: Dow Jones Industrial Average, S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
